Vir, GlaxoSmithKline Begin Phase 2/3 Study of Covid-19 Treatment
August 31 2020 - 9:26AM
Dow Jones News
By Matt Grossman
Vir Biotechnology Inc. and GlaxoSmithKline Plc have dosed the
first patient in a Phase 2/3 study of the use of a monoclonal
antibody for early treatment of Covid-19 patients.
The study will eventually enroll 1,300 patients world-wide to
determine whether the monoclonal antibody, VIR-7831, can prevent
hospitalization due to the coronavirus.
The companies expect results to be completed in the first
quarter of next year, with the possibility of initial results
before the end of 2020. Early access to the treatment may be
available in the first half of next year, the companies said.
Monoclonal antibodies are cloned from immune cells in a
laboratory. Pre-clinical studies of VIR-7831 showed that the
antibody has a high potency in neutralizing SARS-CoV-2, the virus
that causes Covid-19.
In the study, patients with moderate or mild Covid-19 who are at
high risk of progressing to severe disease will be given an
intravenous infusion of VIR-7831, aiming to prevent their
hospitalization or death.
The companies later this year plan to launch a Phase 2 trial of
another antibody, VIR-7832, which also may serve as a prophylactic
against the disease.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
August 31, 2020 09:11 ET (13:11 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024
